RY 173.53 0.0461% SHOP 159.5 1.56% TD 76.22 0.8068% ENB 60.09 0.0333% BN 82.79 0.988% TRI 234.13 -0.1706% CNQ 43.47 0.6949% CP 105.63 0.4756% CNR 148.07 0.5637% BMO 139.11 -0.2152% BNS 77.03 -0.0649% CSU 4547.4502 0.8243% CM 92.53 0.2383% MFC 44.05 0.0454% ATD 80.59 0.1989% NGT 54.92 0.1459% TRP 66.54 0.2561% SU 50.61 0.4765% WCN 248.6 1.1885% L 191.07 -0.4325%
Last update at 2024-12-24T17:59:00Z
Is Fresenius SE & Co. (FSNUY) Stock Undervalued Right Now?
Thu 10 Oct 24, 01:40 PMHere's Why Fresenius (FMS) is a Strong Momentum Stock
Fri 04 Oct 24, 01:50 PMWhy Fresenius (FMS) is a Top Value Stock for the Long-Term
Fri 20 Sep 24, 01:40 PMWhy Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Wed 18 Sep 24, 01:50 PMShould You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €33.88?
Wed 11 Sep 24, 12:31 PMSteris (STE) Up 3% Since Last Earnings Report: Can It Continue?
Thu 05 Sep 24, 03:31 PMReturns On Capital At Fresenius SE KGaA (ETR:FRE) Paint A Concerning Picture
Mon 26 Aug 24, 07:08 AMHere's Why Fresenius (FMS) is a Strong Value Stock
Tue 23 Jul 24, 01:40 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2814.00M | 3652.00M | 3726.00M | 3912.00M | 4664.00M |
| Minority interest | -745.00000M | -1001.00000M | 9074.00M | 9802.00M | 9597.00M |
| Net income | 2117.00M | 2819.00M | 2823.00M | 3029.00M | 2027.00M |
| Selling general administrative | 5524.00M | 4394.00M | 4373.00M | 4386.00M | 3857.00M |
| Selling and marketing expenses | 1220.00M | 1059.00M | 1057.00M | 1020.00M | 1016.00M |
| Gross profit | 10725.00M | 10311.00M | 10316.00M | 10348.00M | 9834.00M |
| Reconciled depreciation | 2973.00M | 2667.00M | 2715.00M | 2452.00M | 1430.00M |
| Ebit | 3508.00M | 4158.00M | 4385.00M | 4631.00M | 4797.00M |
| Ebitda | 6481.00M | 6949.00M | 7162.00M | 7216.00M | 6227.00M |
| Depreciation and amortization | 2973.00M | 2791.00M | 2777.00M | 2585.00M | 1430.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 3508.00M | 4158.00M | 4385.00M | 4631.00M | 5251.00M |
| Other operating expenses | 37519.00M | 33362.00M | 31923.00M | 30807.00M | 29088.00M |
| Interest expense | 694.00M | 630.00M | 752.00M | 881.00M | 942.00M |
| Tax provision | 697.00M | 833.00M | 903.00M | 883.00M | 950.00M |
| Interest income | 187.00M | 124.00M | 93.00M | 162.00M | 355.00M |
| Net interest income | -507.00000M | -506.00000M | -659.00000M | -719.00000M | -587.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 697.00M | 833.00M | 903.00M | 883.00M | 950.00M |
| Total revenue | 40840.00M | 37520.00M | 36277.00M | 35409.00M | 33530.00M |
| Total operating expenses | 7404.00M | 6153.00M | 5962.00M | 5746.00M | 5392.00M |
| Cost of revenue | 30115.00M | 27209.00M | 25961.00M | 25061.00M | 23696.00M |
| Total other income expense net | -694.00000M | -506.00000M | -659.00000M | -719.00000M | -587.00000M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 2117.00M | 2819.00M | 2823.00M | 3029.00M | 3714.00M |
| Net income applicable to common shares | 1372.00M | 1818.00M | 1707.00M | 1883.00M | 2027.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 76415.00M | 71962.00M | 66646.00M | 67006.00M | 56703.00M |
| Intangible assets | 4399.00M | 3831.00M | 3736.00M | 3869.00M | 3130.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 845.00M | 564.00M | 527.00M | 553.00M | 478.00M |
| Total liab | 44197.00M | 42674.00M | 40623.00M | 40426.00M | 31695.00M |
| Total stockholder equity | 20415.00M | 18998.00M | 16949.00M | 16778.00M | 15411.00M |
| Deferred long term liab | - | 708.00M | 681.00M | 665.00M | 640.00M |
| Other current liab | 8552.00M | 2424.00M | 2170.00M | 1943.00M | 5906.00M |
| Common stock | 563.00M | 558.00M | 557.00M | 557.00M | 556.00M |
| Capital stock | 563.00M | 558.00M | 557.00M | 557.00M | 556.00M |
| Retained earnings | - | 14860.00M | -1135.00000M | -190.00000M | -330.00000M |
| Other liab | - | 5229.00M | 5267.00M | 4740.00M | 4380.00M |
| Good will | 31444.00M | 28943.00M | 26599.00M | 27737.00M | 25713.00M |
| Other assets | - | 2442.00M | 2220.00M | 2231.00M | 2210.00M |
| Cash | 2175.00M | 2610.00M | 1837.00M | 1654.00M | 2709.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13658.00M | 15062.00M | 13216.00M | 13884.00M | 13275.00M |
| Current deferred revenue | - | 5827.00M | 5560.00M | 4528.00M | 452.00M |
| Net debt | 25588.00M | 24545.00M | 24076.00M | 25604.00M | 16425.00M |
| Short term debt | 3036.00M | 4772.00M | 3670.00M | 5508.00M | 5094.00M |
| Short long term debt | 2185.00M | 3940.00M | 2904.00M | 4715.00M | 4944.00M |
| Short long term debt total | 27763.00M | 27155.00M | 25913.00M | 27258.00M | 19134.00M |
| Other stockholder equity | 19852.00M | 18440.00M | 17527.00M | 16411.00M | 15185.00M |
| Property plant equipment | 18841.00M | 18583.00M | 17603.00M | 17266.00M | 10366.00M |
| Total current assets | 18279.00M | 17461.00M | 15772.00M | 15264.00M | 14790.00M |
| Long term investments | - | - | - | 1304.00M | 1134.00M |
| Net tangible assets | - | -13068.00000M | -12705.00000M | -14163.00000M | -12792.00000M |
| Short term investments | 170.00M | 136.00M | 161.00M | 133.00M | 100.00M |
| Net receivables | 10256.00M | 9933.00M | 9302.00M | 9291.00M | 8285.00M |
| Long term debt | 18986.00M | 27155.00M | 16821.00M | 16104.00M | 14040.00M |
| Inventory | 4833.00M | 4218.00M | 3945.00M | 3633.00M | 3218.00M |
| Accounts payable | 2070.00M | 2039.00M | 1816.00M | 1905.00M | 1823.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 1499.00M | 1012.00M | 888.00M | 861.00M | 898.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 58136.00M | 54501.00M | 50874.00M | 51742.00M | 41913.00M |
| Capital lease obligations | 6592.00M | 6590.00M | 6188.00M | 6439.00M | 150.00M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2607.00000M | -7.00000M | -33.00000M | 26.00M | 1093.00M |
| Change to liabilities | 0.00000M | -154.00000M | 1819.00M | 67.00M | 223.00M |
| Total cashflows from investing activities | -2607.00000M | -2817.00000M | -3011.00000M | -4856.00000M | -1464.00000M |
| Net borrowings | - | -398.00000M | -1695.00000M | 1019.00M | -433.00000M |
| Total cash from financing activities | -1604.00000M | -1452.00000M | -3117.00000M | -484.00000M | -1273.00000M |
| Change to operating activities | - | -320.00000M | -252.00000M | -368.00000M | -345.00000M |
| Net income | 2117.00M | 2819.00M | 2823.00M | 3029.00M | 3714.00M |
| Change in cash | -15.00000M | 927.00M | 183.00M | -1055.00000M | 1073.00M |
| Begin period cash flow | 2764.00M | 1837.00M | 1654.00M | 2709.00M | 1636.00M |
| End period cash flow | 2749.00M | 2764.00M | 1837.00M | 1654.00M | 2709.00M |
| Total cash from operating activities | 4198.00M | 5078.00M | 6549.00M | 4263.00M | 3742.00M |
| Issuance of capital stock | 20.00M | 38.00M | 18.00M | 49.00M | 92.00M |
| Depreciation | 2973.00M | 2667.00M | 2715.00M | 2452.00M | 1430.00M |
| Other cashflows from investing activities | - | - | - | - | 0.00000M |
| Dividends paid | 890.00M | 1068.00M | 1060.00M | 952.00M | 904.00M |
| Change to inventory | -472.00000M | -105.00000M | -527.00000M | -315.00000M | -279.00000M |
| Change to account receivables | - | 77.00M | -13.00000M | -593.00000M | -544.00000M |
| Sale purchase of stock | - | 5571.00M | -366.00000M | -600.00000M | -37.00000M |
| Other cashflows from financing activities | 3466.00M | -24.00000M | 3595.00M | 5763.00M | 1577.00M |
| Change to netincome | - | 1127.00M | 1294.00M | 1110.00M | 976.00M |
| Capital expenditures | 1917.00M | 2047.00M | 2406.00M | 2459.00M | 3219.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -661.00000M | -534.00000M | 1028.00M | -1182.00000M | -691.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -231.00000M | 126.00M | -17.00000M | -36.00000M | -711.00000M |
| Free cash flow | 2281.00M | 3031.00M | 4143.00M | 1804.00M | 523.00M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FSNUY Fresenius SE & Co KGaA ADR |
-0.01 0.11% | 8.76 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| HCA HCA Holdings Inc |
-2.06 0.68% | 302.56 | 13.19 | 13.66 | 1.13 | 293.44 | 1.77 | 8.22 |
| FSNUF Fresenius SE & Co. KGaA |
-0.001 0.003% | 32.85 | 16.76 | 9.62 | 0.42 | 0.79 | 0.78 | 5.31 |
| JDHIY JD Health International Inc |
- -% | 3.81 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
| JDHIF JD Health International Inc |
- -% | 3.12 | 57.75 | 32.68 | 0.29 | 2.11 | 0.16 | 3.90 |
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, Germany, 61352
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Sen | CEO, Pres & Chairman of Management Board - Fresenius Management SE | 1968 |
| Dr. Francesco De Meo | Member of Management Board - Fresenius Management SE | 1963 |
| Dr. Ernst Wastler | Member of Management Board - Fresenius Management SE | 1958 |
| Dr. Sebastian Biedenkopf | Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board | 1964 |
| Ms. Sara Hennicken | CFO & Member of the Management Board - Fresenius Management SE | 1980 |
| Ms. Helen Giza | Member of the Management Board - Fresenius Management SE | 1968 |
| Mr. Markus Georgi | Sr. VP of Investor Relations | NA |
| Matthias Link | Sr. VP Corp. Communications | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...